A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2010
At a glance
- Drugs ABT 384 (Primary)
- Indications Alzheimer's disease; Neurological disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 13 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2010 Planned end date changed from 1 Sep 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov
- 01 Jul 2010 Planned end date changed from 1 Aug 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov